Stock info Celyad | Filter  Basic-Info

Celyad

Celyad's core business is the biotech sector. Over the past 10 years the global biotech companies gained around 59 percent. Measured since 2011 the sector is 70 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 59 percent.

The past year was a profitable year for the Celyad investors

Over the past year the company' stock lost around 62 percent. Over the past 5 years Celyad' stock lost at around 0 percent in value. Celyad's revenues between 2011 and 2015 were very volatile and moved between 0,05 million euros and 0 million euros. Celyad's net results between 2011 and 2015 were quite unstable and moved between -9,35 million euros and -29,11 million euros.

The Belgian company didn't pay out any dividends (in the past 5 years).

Celyad financed with a quite low debt position

At the end of 2015 the Belgian company's balance sheet was worth 159,53 million euros. The total debt of the biotech company was at the end of 2015 48,06 million euros, which equals around 30,13 percent of the total balance sheet. The Belgian company's price/earnings-ratio was -10. So the market valued the stock at -10 times the 2015' earnings per share. Based on it's price/earnings-ratio and dividend yield the Belgian stock can be seen as a value stock.

The biotech company's market capitalization (the number of shares outstanding times the market value) equaled around 403,69 million euros. At the end of 2015 the Belgian company had around 8,49 million stocks listed.

All Celyad's annual reports can be found here. More information about Celyad can be found it's website. .